Edesa Biotech, Inc.
EDSA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.05 | -0.01 | 0.09 |
| FCF Yield | -12.28% | -18.02% | -27.00% | -6.80% |
| EV / EBITDA | -1.12 | 0.61 | -2.58 | -14.39 |
| Quality | ||||
| ROIC | -13.47% | -10.55% | -83.87% | -50.19% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 1.00 | 1.47 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 24.95% | -53.77% | -56.89% | -12.91% |
| Safety | ||||
| Net Debt / EBITDA | 7.29 | 8.88 | 0.99 | 1.11 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,347.72 | -3,358.89 | -3,967.15 | 0.00 |